IGBA Still Sees A Path To Change FDA’s Mind On Biologic Suffixes

 
• By Dave Wallace
  
Digital globe
The IGBA’s Secretary General And Chair Give Us The Latest On Global Issues Affecting The Generics And Biosimilars Industries • Source: Shutterstock

More from Regulation

More from Policy & Regulation